Labs / CDMO: development & manufacturing
Ailux
Shanghai, China · ailuxbio.com
Ailux develops AI-enabled biologic therapies for immune-mediated diseases. It operates across early R&D in the United States, translational medicine in the United Kingdom, and clinical development in China.
They take quote requests by email.
What they offer
AI-native biologics discovery and development
Uses AI, proprietary data, and wet-lab validation to move biologic candidates from target identification through optimization and translational science.
AI platform licensing
Licenses its proprietary AI platform technology, including XtalFold®, to external partners.
Comprehensive wet-lab evaluation
Tests AI-generated designs through high-throughput, large-scale specialized assays in-house.
Biologics therapeutic design
Develops de novo and multiparametric optimized biologic candidates with complex multispecific architectures.
What they work on
- Modalities
- Antibody, Bispecific
- Assays and studies
- high-throughput specialized assays, wet-lab validation
- Scale and capacity
- 30,000+ sq. ft. wet lab, 3 strategic hubs, 180 employees
- Therapeutic areas
- immune-mediated diseases, respiratory, immunology
- Sites
- Somerville, United States · Shanghai, China
- Team
- 180 employees
- Serves
- United States, United Kingdom, China, global
- Address
- 100 Chestnut Street Suite 300 Somerville, MA 02143
Similar labs. Alphalyse, Asimov, Aurigene Pharmaceutical Services, Avid Bioservices
Found in a contract services directory. Listing built from ailuxbio.com. Work here? Claim this listing.